Inclusion Criteria:

• Age ≥18 years seen at MMBC clinic in Rochester.

• Diagnosis of bronchiectasis confirmed by MMBC provider and chest CT.

• Within the last 3 months - culture growth of a mold in high quantity (‘many’) or culture growth of at least two distinct mold species in any quantity

• Not actively on antimicrobial therapy AND no current plan to initiate antimicrobia therapy at the time of enrollment, as determined by the treating provider.

• Ability to produce spontaneous sputum at Visit 1.

Exclusion Criteria:

• Known diagnosis of allergic bronchopulmonary aspergillosis or invasive fungal disease.

• Use of the following medications: rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, dofetilide, quinidine, dronedarone, simvastatin, lovastatin, certain immunosuppressants (tacrolimus, cyclosporine, sirolimus, everolimus) and anticoagulants (rivaroxaban, apixaban, edoxaban, warfarin).

• Abnormal baseline liver function tests (ALT, AST, alkaline phosphatase, or bilirubin >upper limit of normal)

• Prolonged QTc interval on baseline ECG (>460 ms in females or >450 ms in males)

• History of congestive heart failure (black box warning), known cardiomyopathy, or arrhythmias.

• Pregnancy or lactation

• Prior use of systemic antifungals within the past 3 months.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/10/2025. Questions regarding updates should be directed to the study team contact.